Irritable Bowel Syndrome with Diarrhea
📧 Sign up to get email alerts when something new happens for Irritable Bowel Syndrome with Diarrhea.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 4]
Phase 4 clinical trial update evaluating efficacy and safety of a probiotic formulation in adults with irritable bowel syndrome with diarrhe…
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) [Phase 2]
Phase 2 trial of aldafermin (NGM282) for chronic diarrhea due to bile acid malabsorption has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea [Phase 4]
Phase 4 clinical trial comparing combination therapies for irritable bowel syndrome with diarrhea has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Efficacy and Safety of Rifaximin With NAC in IBS-D [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating rifaximin with N-acetylcysteine for irritable bowel syndrome with diarrhea (IBS-D); results posted in…
-
CLINICAL_TRIALS trial_result · 2023-03-06Clinical Trial Update: Lactobacillus LB as Treatment for Irritable Bowel Syndrome With Predominance of Diarrhea (IBS-D) [Phase 4]
Phase 4 trial update evaluating Lactobacillus LB for Irritable Bowel Syndrome with Diarrhea (IBS-D).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Efficacy and Safety of DT01 Tablets in Patients With Irritable Bowel Syndrome With Diarrhea [Phase 2]
A Phase 2 clinical trial assessing the efficacy and safety of DT01 tablets in patients with irritable bowel syndrome with diarrhea.
-
FDA approval · 2023-01-26FDA Approved: LOPERAMIDE HYDROCHLORIDE — Original Application (Advagen Pharma Ltd.,)
FDA approved Advagen Pharma Ltd.'s original application for loperamide hydrochloride (a generic anti-diarrheal) to treat various forms of di…
-
CLINICAL_TRIALS trial_result · 2022-10-12Clinical Trial Update: Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) [Phase 2]
This trial update reports termination of the Phase 2 study of olorlinab for irritable bowel syndrome, including IBS with constipation and IB…
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Intestinal Permeability and Intestinal Microbiota in Irritable Bowel Syndrome [Phase 4]
Phase 4 clinical trial update examining intestinal permeability and microbiota in Irritable Bowel Syndrome with Diarrhea.
-
FDA approval · 2022-05-05FDA Approved: ALOSETRON HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for alosetron hydrochloride by Amneal Pharmaceuticals of New York LLC, resulting in generic approval…
-
CLINICAL_TRIALS research · 2022-04-19Clinical Trial Update: Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome [Phase 4]
Phase 4 trial update exploring differences in gut microbiota and metabolomic profiles between rifaximin responders and non-responders in dia…
-
CLINICAL_TRIALS trial_result · 2022-03-04Clinical Trial Update: A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D) [Phase 2]
Phase 2 trial comparing ORP-101 to placebo in adults with irritable bowel syndrome with diarrhea (IBS-D) has completed.
-
FDA approval · 2021-10-18FDA Approved: ALOSETRON HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
FDA approved a supplemental application for alosetron hydrochloride from Amneal Pharmaceuticals of New York LLC.
-
CLINICAL_TRIALS trial_result · 2021-05-19Clinical Trial Update: Eluxadoline Bile Acid Malabsorption (BAM) Study [Phase 4]
Phase 4 trial update for eluxadoline in bile acid malabsorption related to irritable bowel syndrome with diarrhea has completed with results…
-
CLINICAL_TRIALS trial_result · 2021-03-12Clinical Trial Update: A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome [Phase 2]
Phase 2 trial evaluating MD-7246 for abdominal pain in diarrhea-predominant irritable bowel syndrome (IBS-D) has completed with posted resul…
-
EMA withdrawal · 2021-02-25EMA Withdrawn: Truberzi (eluxadoline) — Allergan Pharmaceuticals International Limited
The EMA has withdrawn Truberzi (eluxadoline) from the market for irritable bowel syndrome with diarrhea.
-
CLINICAL_TRIALS research · 2020-07-28Clinical Trial Update: Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D [Phase 4]
Phase 4 trial investigating continuous rifaximin with probiotics on gut microbiota in irritable bowel syndrome with diarrhea patients.
-
FDA approval · 2020-06-17FDA Approved: VIBERZI — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for VIBERZI (eluxadoline) submitted by Allergan, Inc. The action concerns the product and its labeli…
-
CLINICAL_TRIALS trial_result · 2020-04-27Clinical Trial Update: Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption [Phase 2]
Phase 2 trial evaluating colesevelam for diarrhea-predominant irritable bowel syndrome with bile acid malabsorption has completed with poste…
-
CLINICAL_TRIALS trial_result · 2019-10-04Clinical Trial Update: The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome [NA]
A completed clinical trial evaluating PX0612 for irritable bowel syndrome with diarrhea; results posted in 2019.
-
FDA approval · 2019-09-16FDA Approved: ALOSETRON HYDROCHLORIDE — Original Application (Eywa Pharma Inc)
FDA approved Eywa Pharma Inc's original ANDA for alosetron hydrochloride, a generic version of the IBS with diarrhea treatment.
-
FDA approval · 2019-05-28FDA Approved: LOPERAMIDE HYDROCHLORIDE — Supplemental Application (Aurohealth LLC)
FDA approved a supplemental application for loperamide hydrochloride from Aurohealth LLC under ANDA206548, confirming the regulatory status …
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use [Phase 4]
Phase 4 trial evaluating eluxadoline for irritable bowel syndrome with diarrhea in patients with inadequate relief from prior loperamide; st…
-
CLINICAL_TRIALS trial_result · 2018-07-31Clinical Trial Update: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) [Phase 2]
Phase 2 randomized, double-blind trial evaluating BEKINDA (ondansetron 12 mg bimodal release) for diarrhea-predominant irritable bowel syndr…
-
FDA label_change · 2018-06-26FDA Approved: VIBERZI — Supplemental Application (Allergan, Inc.)
Supplemental application for VIBERZI (eluxadoline) submitted by Allergan, Inc., seeking changes to the product labeling.